Evidence map›Paper›PMID 29354331›Full record

ArticleNMC case report journal2018

Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage Therapy.

Yasuhiro Kawabata, Tomokazu Aoki, Tetsurou Yamamoto, Hisateru Yasui, Satoru Sawai, Shunichi Fukuda, Satoru Kawarazaki, Tetsuya Tsukahara

Open access · diamondAbstract readCase Reports
In one paragraph

Article in NMC case report journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yasuhiro KawabataDepartment of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Tomokazu AokiDepartment of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Tetsurou YamamotoDepartment of Pathology, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Hisateru YasuiDepartment of Medical Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Satoru SawaiDepartment of Chest Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Shunichi FukudaDepartment of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Satoru KawarazakiDepartment of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Tetsuya TsukaharaDepartment of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
Kyoto Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary intracranial leiomyosarcoma (LMS) is an extremely rare tumor of the central nervous system. Only sporadic case reports have been published, and therefore data regarding long-term prognosis remain scarce. A 76-year-old woman presented with a right parietal mass, which had grown rapidly in the month prior to admission. Neuroimaging showed a resemblance to intraosseous meningioma. Gross total resection of the tumor was achieved, and histological diagnosis confirmed LMS. Because positron emission tomography (PET) with fluorodeoxyglucose (FDG) just after the resection showed no abnormal uptake, we diagnosed the tumor as primary intracranial LMS. Follow-up PET at 16 months after treatment showed two foci of FDG uptake in the bilateral lungs. Histological diagnosis by surgical resection identified the lesions as lung metastases of LMS. In addition, follow-up head magnetic resonance imaging (MRI) at 31 months showed local recurrence, and we conducted salvage therapy using CyberKnife system (Accuray incorporated) and pazopanib. To date, for 15 months after local recurrence, she is alive with intracranial recurrent disease remained inactive.

Indexed as

leiomyosarcomalocal recurrencelung metastasispazopanib

Identifiers

PMID29354331
PMCPMC5767479
OpenAlexW2771882227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.